Form 4: Director Nina Kjellson Receives Eloxx Stock Options

Director Nina S. Kjellson was granted 13,587 stock options in Eloxx Pharmaceuticals, Inc. as part of a standard equity compensation plan.

Summary

• Director Nina S. Kjellson received a grant of 13,587 stock options on June 8, 2026.
• The options have an exercise price of $11.00 per share.
• The options are set to expire on June 8, 2036.
• The grant vests in 24 substantially equal monthly installments over two years, contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on the company's financial outlook.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Vesting is subject to the Reporting Person's continuous service to the Issuer.

Future Outlook

The options vest over a 24-month period, indicating a commitment to the company's service through June 2028.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board alignment with company performance.

Comparison to Industry Standards

• The 24-month vesting schedule is consistent with standard equity incentive plans for board members in small-cap pharmaceutical companies.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options in monthly installments over the next 24 months.

Key Dates

Keywords

Eloxx Pharmaceuticals, ELOX, Form 4, Insider Trading, Stock Options, Director Compensation